Cargando…

NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas

BACKGROUND: The determination of NRAS and BRAF mutation status is a major requirement in the treatment of patients with metastatic melanoma. Mutation specific antibodies against NRAS(Q61R) and BRAF(V600E) proteins could offer additional data on tumor heterogeneity. The specificity and sensitivity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uguen, Arnaud, Talagas, Matthieu, Costa, Sebastian, Samaison, Laura, Paule, Laure, Alavi, Zarrin, De Braekeleer, Marc, Le Marechal, Cédric, Marcorelles, Pascale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513673/ https://www.ncbi.nlm.nih.gov/pubmed/26204954 http://dx.doi.org/10.1186/s13000-015-0359-0

Ejemplares similares

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma
por: Uguen, Arnaud, et al.
Publicado: (2015)

Fluorescence in situ hybridization testing of chromosomes 6, 8, 9 and 11 in melanocytic tumors is difficult to automate and reveals tumor heterogeneity in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2016)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

ODP465 BRAF V600 and NRAS Q61 mutations in thyroid fine-needle aspiration (FNA) with indeterminate cytology in Argentina
por: Repetto, Esteban M, et al.
Publicado: (2022)

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations
por: Prabhakaran, Nitya, et al.
Publicado: (2023)

Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
por: Vallée, Audrey, et al.
Publicado: (2019)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
por: Mercier, Anaïs, et al.
Publicado: (2023)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy
por: McGrail, Kimberley, et al.
Publicado: (2022)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma
por: Zablocka, Tatjana, et al.
Publicado: (2022)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
por: Ida, Cristiane M, et al.
Publicado: (2013)

BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
por: Breton, Quentin, et al.
Publicado: (2017)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry
por: Urvanegia, Ana Claudia, et al.
Publicado: (2017)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer
por: Schafroth, Christian, et al.
Publicado: (2015)

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
por: Schirosi, Laura, et al.
Publicado: (2016)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Transcriptome of melanoma cells from two mouse models, Tyr:NRas(Q61K)and Tyr:Rack1-HA, Tyr:NRas(Q61K)
por: Campagne, Cécil, et al.
Publicado: (2017)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

The Histopathological “Placentitis Triad” Is Specific for SARS-CoV-2 Infection, and Its Acute Presentation Can Be Associated with Poor Fetal Outcome
por: Remoué, Annabelle, et al.
Publicado: (2023)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023)

Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test
por: Durślewicz, Justyna, et al.
Publicado: (2020)

The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma
por: Ramkumar, Subramaniam, et al.
Publicado: (2021)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dkt3elho90h80ughb6o0krqscc